7811 Montrose Rd Suite 310
Potomac, MD 20854


Why Eskata?

Until now there have been no FDA-approved topical treatments for raised SKs.

Raised seborrheic keratoses (SKs) are known to appear in highly visible locations

Common treatment modalities:

Many patients are willing to self-pay for SK treatment

*Survey not limited to patients with raised SKs.

The Eskata Difference

FDA-Approved Formulation

  • ESKATA contains 40% pharmaceutical grade H2O2 (hydrogen peroxide) that meets FDA guidelines and is FDA-approved for the treatment of raised seborrheic keratoses
  • The active pharmaceutical ingredient is housed in a proprietary solution that increases spreadability while maintaining stability(4)
  • This unique combination was evaluated in pivotal trials that included over 900 subjects*

Novel Application

  • Doe-foot applicator
  • Applicator tip design allows optimal spreadability over targeted lesions
  • Flame-sealed crushable ampule provides shelf stability for 2 years at room temperature


  1. Data on file. Aclaris Therapeutics, Inc. 2017.
  2. Jackson JM, Alexis A, Berman B, Berson DS, Taylor S, Weiss JS. Current Understanding of Seborrheic Keratosis: Prevalence, Etiology, Clinical Presentation, Diagnosis, and Management. J Drugs Dermatol. 2015;14(10):1119-1125.
  3. Hafner C, Vogt T. Seborrheic keratosis. J Dtsch Dermatol Ges. 2008;6(8):664-667.
  4. ESKATA Full Prescribing Information. Aclaris Therapeutics, Inc. 2017.

Schedule Consultation